Autopsy report · NCT01514149
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
Cause of deathFunding or business
“Business decision”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year 6 months before it stopped.
- 73 participants enrolled.
- Results were posted on the registry 4 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- ConjuChem
- Sponsor type
- Industry
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- CJC-1134-PC Injection; Weekly placebo for CJC-1134-PC Injection
- Participants
- 73
- Sites
- 22
- Countries
- Canada, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.